Whole-genome fingerprint of the DNA methylome during chemically induced differentiation of the human AML cell line HL-60/S4.


Journal

Biology open
ISSN: 2046-6390
Titre abrégé: Biol Open
Pays: England
ID NLM: 101578018

Informations de publication

Date de publication:
17 02 2020
Historique:
pubmed: 29 1 2020
medline: 29 1 2020
entrez: 29 1 2020
Statut: epublish

Résumé

Epigenomic regulation plays a vital role in cell differentiation. The leukemic HL-60/S4 [human myeloid leukemic cell line HL-60/S4 (ATCC CRL-3306)] promyelocytic cell can be easily differentiated from its undifferentiated promyelocyte state into neutrophil- and macrophage-like cell states. In this study, we present the underlying genome and epigenome architecture of HL-60/S4 through its differentiation. We performed whole-genome bisulphite sequencing of HL-60/S4 cells and their differentiated counterparts. With the support of karyotyping, we show that HL-60/S4 maintains a stable genome throughout differentiation. Analysis of differential Cytosine-phosphate-Guanine dinucleotide methylation reveals that most methylation changes occur in the macrophage-like state. Differential methylation of promoters was associated with immune-related terms. Key immune genes,

Identifiants

pubmed: 31988093
pii: bio.044222
doi: 10.1242/bio.044222
pmc: PMC7044446
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Informations de copyright

© 2020. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare no competing or financial interests.

Références

Nat Rev Genet. 2011 Apr;12(4):283-93
pubmed: 21358745
Nat Genet. 2015 Jul;47(7):746-56
pubmed: 26053498
Cell. 1987 Jan 16;48(1):39-46
pubmed: 3791414
Cell. 1997 Nov 28;91(5):661-72
pubmed: 9393859
Science. 2010 Feb 5;327(5966):656-61
pubmed: 20133564
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13158-63
pubmed: 8917561
Mol Cell. 2012 Aug 24;47(4):633-47
pubmed: 22841485
Nat Biotechnol. 2010 May;28(5):495-501
pubmed: 20436461
Nucleus. 2017 Mar 4;8(2):188-204
pubmed: 28406749
FEBS Lett. 1999 Feb 5;444(1):5-10
pubmed: 10037138
Immunity. 2007 Jun;26(6):726-40
pubmed: 17582345
BMC Bioinformatics. 2009 Jul 27;10:232
pubmed: 19635165
Front Immunol. 2014 Sep 03;5:423
pubmed: 25232355
Genome Res. 2012 Dec;22(12):2497-506
pubmed: 22960375
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Nature. 2014 Mar 27;507(7493):455-461
pubmed: 24670763
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Annu Rev Genet. 2008;42:733-72
pubmed: 18729722
BMC Genomics. 2017 Feb 14;18(1):158
pubmed: 28196481
Exp Cell Res. 1998 Nov 25;245(1):91-104
pubmed: 9828104
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15841-6
pubmed: 23019368
Proc Natl Acad Sci U S A. 1981 Jun;78(6):3863-6
pubmed: 6943586
Exp Cell Res. 2000 Jan 10;254(1):130-42
pubmed: 10623473
Nucleus. 2014 May-Jun;5(3):237-46
pubmed: 24824428
Nat Rev Immunol. 2015 Jan;15(1):7-17
pubmed: 25534619
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
Bioinformatics. 2015 Aug 1;31(15):2560-4
pubmed: 25788621
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
J Biol Chem. 2001 May 25;276(21):17920-31
pubmed: 11279020
Nucleic Acids Res. 2007 Jan;35(Database issue):D88-92
pubmed: 17130149
Cell Stem Cell. 2016 Dec 1;19(6):808-822
pubmed: 27867036
Genome Res. 2012 Sep;22(9):1760-74
pubmed: 22955987
Nat Rev Genet. 2018 Dec;19(12):789-800
pubmed: 30367165
Annu Rev Immunol. 2006;24:705-38
pubmed: 16551264
Genome Res. 2012 Sep;22(9):1711-22
pubmed: 22955983
Exp Cell Res. 1992 Mar;199(1):154-61
pubmed: 1735455
Biochim Biophys Acta. 2007 Jan;1775(1):138-62
pubmed: 17045745
Genome Biol. 2012 Jul 11;13(7):R61
pubmed: 22784381
Nat Rev Genet. 2013 Mar;14(3):204-20
pubmed: 23400093
EMBO J. 1994 Dec 15;13(24):6087-98
pubmed: 7813445
Cancer Cell. 2014 Oct 13;26(4):577-90
pubmed: 25263941
Nat Rev Genet. 2012 May 29;13(7):484-92
pubmed: 22641018
PLoS One. 2011 Jan 18;6(1):e14524
pubmed: 21267076
Nucleus. 2017 Mar 4;8(2):222-237
pubmed: 28152343
Nucleic Acids Res. 2013 Jan;41(Database issue):D56-63
pubmed: 23193274
Genome Res. 2009 Jun;19(6):1044-56
pubmed: 19273619
Br J Cancer Suppl. 1988 Dec;9:41-5
pubmed: 3076064

Auteurs

Enoch B Antwi (EB)

Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Molecular and Cellular Engineering, Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Heidelberg Biosciences International Graduate School (HBIGS), Heidelberg, Germany.

Ada Olins (A)

Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland, ME, USA.

Vladimir B Teif (VB)

School of Life Sciences, University of Essex, Colchester, UK.

Matthias Bieg (M)

Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health.
Digital Health Centre, Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178 Berlin, Germany.

Tobias Bauer (T)

Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Zuguang Gu (Z)

Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Benedikt Brors (B)

Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Consortium (DKTK), Core Center, Heidelberg, Germany.

Roland Eils (R)

Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health.
Digital Health Centre, Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178 Berlin, Germany.
Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), University of Heidelberg, Heidelberg, Germany.

Donald Olins (D)

Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland, ME, USA.

Naveed Ishaque (N)

Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany naveed.ishaque@charite.de.
Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health.
Digital Health Centre, Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178 Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH